StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Thursday. The firm set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark reissued a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Price Performance

Shares of NASDAQ BIOL opened at $0.01 on Thursday. The stock has a market capitalization of $300,663.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 12 month low of $0.02 and a 12 month high of $1.94. The firm’s 50 day simple moving average is $0.01 and its 200-day simple moving average is $0.03.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.